Hikma Pharmaceutical - Director/PDMR Shareholding

Hikma Pharmaceuticals

06/05/2026 15:08

RNS Number : 2912D

Hikma Pharmaceuticals Plc

06 May 2026

 

Hikma Pharmaceuticals PLC

(the "Company")

 

LONDON, 6 May 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the below listed Persons Discharging Managerial Responsibilities ("PDMRs") of the Company acquired Ordinary Shares in the Company, which were purchased under a dividend reinvestment plan ("DRIP").

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities

Hussein Arkhagha

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Hussein Arkhagha
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Acquisition of Ordinary Shares through participation in a DRIP.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.098
407
d)
Aggregated information
Price(s): £14.098
Volume(s):407
Total: £5,737.82
e)
Date of the transaction
5 May 2026
f)
Place of the transaction
London Stock Exchange (XLON)

Susan Ringdal

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Susan Ringdal
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Acquisition of Ordinary Shares through participation in a DRIP.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.098
2,337
d)
Aggregated information
Price(s): £14.098
Volume(s):2,337
Total: £32,946.63
e)
Date of the transaction
5 May 2026
f)
Place of the transaction
London Stock Exchange (XLON)

Julie Hill

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Julie Hill
2
Reason for the notification
a)
Position/status
PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Hikma Pharmaceuticals PLC
b)
LEI
549300BNS685UXH4JI75
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument and identification code
Description: Ordinary shares of 10 pence each (Shares)
ID Code: GB00B0LCW083
b)
Nature of the transaction
Acquisition of Ordinary Shares through participation in a DRIP.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.098
178
d)
Aggregated information
Price(s): £14.098
Volume(s):178
Total: £2,509.41
e)
Date of the transaction
5 May 2026
f)
Place of the transaction
London Stock Exchange (XLON)

 

 

Helen Middlemist

Group Company Secretary

+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHBSGDULGGDGLL